Role of the innate and adaptive immune responses in the course of multiple sclerosis

The Lancet Neurology

Volumn 14, Issue 4, 2015, Pages 406-419

  Hemmer, Bernhard ^a,c   Kerschensteiner, Martin ^b,c   Korn, Thomas ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Munich Cluster for Systems Neurology ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTIVE IMMUNITY; ANTIGEN RECOGNITION; ASTROCYTE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE COURSE; DISEASE PREDISPOSITION; GENETIC SUSCEPTIBILITY; HISTOPATHOLOGY; HUMAN; INNATE IMMUNITY; MACROPHAGE; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW; ANIMAL; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL (TOPIC); DISABLED PERSON; DISEASE MODEL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOLOGY; INCIDENCE; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM; STATISTICS AND NUMERICAL DATA; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANIMALS; CENTRAL NERVOUS SYSTEM; CLINICAL TRIALS AS TOPIC; DISABLED PERSONS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNITY, INNATE; INCIDENCE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PERIPHERAL NERVOUS SYSTEM; T-LYMPHOCYTES;

EID: 84926336855     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70305-9     Document Type: Review

References (148)

1. Koch-Henriksen N, Sørensen PS The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010, 9:520-532.
2. Buck D, Hemmer B Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol 2011, 258:1747-1762.
3. Auffray C, Sieweke MH, Geissmann F Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009, 27:669-692.
4. Murray PJ, Wynn TA Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11:723-737.
5. Geissmann F, Gordon S, Hume DA, Mowat AM, Randolph GJ Unravelling mononuclear phagocyte heterogeneity. Nat Rev Immunol 2010, 10:453-460.
6. Sica A, Mantovani A Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012, 122:787-795.
7. Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841-845.
8. Prinz M, Priller J, Sisodia SS, Ransohoff RM Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci 2011, 14:1227-1235.
9. Butovsky O, Jedrychowski MP, Moore CS, et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci 2014, 17:131-143.
10. Ransohoff RM, Cardona AE The myeloid cells of the central nervous system parenchyma. Nature 2010, 468:253-262.
11. Kettenmann H, Kirchhoff F, Verkhratsky A Microglia: new roles for the synaptic stripper. Neuron 2013, 77:10-18.
12. Nayak D, Roth TL, McGavern DB Microglia development and function. Annu Rev Immunol 2014, 32:367-402.
13. Nimmerjahn A, Kirchhoff F, Helmchen F Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
14. Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005, 8:752-758.
15. Tremblay ME, Lowery RL, Majewska AK Microglial interactions with synapses are modulated by visual experience. PLoS Biol 2010, 8:e1000527.
16. Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011, 333:1456-1458.
17. Parkhurst CN, Yang G, Ninan I, et al. Microglia promote learning-dependent synapse formation through brain-derived neurotrophic factor. Cell 2013, 155:1596-1609.
18. Harkiolaki M, Holmes SL, Svendsen P, et al. T cell-mediated autoimmune disease due to low-affinity crossreactivity to common microbial peptides. Immunity 2009, 30:348-357.
19. Wildin RS, Ramsdell F, Peake J, et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 2001, 27:18-20.
20. Bennett CL, Christie J, Ramsdell F, et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
21. Josefowicz SZ, Lu LF, Rudensky AY Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012, 30:531-564.
22. Waldner H, Collins M, Kuchroo VK Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest 2004, 113:990-997.
23. Korn T, Bettelli E, Oukka M, Kuchroo VK IL-17 and Th17 Cells. Annu Rev Immunol 2009, 27:485-517.
24. Kaech SM, Ahmed R Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells. Nat Immunol 2001, 2:415-422.
25. van Stipdonk MJ, Lemmens EE, Schoenberger SP Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation. Nat Immunol 2001, 2:423-429.
26. Jankovic M, Casellas R, Yannoutsos N, Wardemann H, Nussenzweig MC RAGs and regulation of autoantibodies. Annu Rev Immunol 2004, 22:485-501.
27. Lanzavecchia A Antigen-specific interaction between T and B cells. Nature 1985, 314:537-539.
28. Fillatreau S, Gray D, Anderton SM Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008, 8:391-397.
29. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219. the International Multiple Sclerosis Genetics Consortium, the Wellcome Trust Case Control Consortium 2the Wellcome Trust Case Control Consortium 2.
30. Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013, 45:1353-1360. the International Multiple Sclerosis Genetics Consortium (IMSGC), the Wellcome Trust Case Control Consortium 2 (WTCCC2)the Wellcome Trust Case Control Consortium 2 (WTCCC2), the International IBD Genetics Consortium (IIBDGC)the International IBD Genetics Consortium (IIBDGC).
31. Farh KK-H, Marson A, Zhu J, et al. Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 2014, 518:337-343.
32. Raj T, Rothamel K, Mostafavi S, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science 2014, 344:519-523.
33. Gregory AP, Dendrou CA, Attfield KE, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 2012, 488:508-511.
34. Ramagopalan SV, Dyment DA, Ebers GC Genetic epidemiology: the use of old and new tools for multiple sclerosis. Trends Neurosci 2008, 31:645-652.
35. Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005, 128:1667-1676.
36. Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 2010, 67:824-830.
37. Simon KC, Munger KL, Xing Yang, Ascherio A Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Mult Scler 2010, 16:133-138.
38. Ascherio A, Munger KL, Simon KC Vitamin D and multiple sclerosis. Lancet Neurol 2010, 9:599-612.
39. Allen AC, Kelly S, Basdeo SA, et al. A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. Mult Scler 2012, 18:1797-1800.
40. Henderson AP, Barnett MH, Parratt JD, Prineas JW Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009, 66:739-753.
41. Sharma R, Fischer M-T, Bauer J, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol 2010, 120:223-236.
42. Barnett MH, Prineas JW Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004, 55:458-468.
43. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000, 47:707-717.
44. Chang A, Tourtellotte WW, Rudick R, Trapp BD Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002, 346:165-173.
45. Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006, 129:3165-3172.
46. Bø L, Vedeler CA, Nyland HI, Trapp BD, Mørk SJ Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neurol 2003, 62:723-732.
47. Geurts JJ, Calabrese M, Fisher E, Rudick RA Measurement and clinical effect of grey matter pathology in multiple sclerosis. Lancet Neurol 2012, 11:1082-1092.
48. Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011, 134:2755-2771.
49. Korn T, Mitsdoerffer M, Kuchroo VK Immunological basis for the development of tissue inflammation and organ-specific autoimmunity in animal models of multiple sclerosis. Results Probl Cell Differ 2010, 51:43-74.
50. Zamvil SS, Mitchell DJ, Moore AC, Kitamura K, Steinman L, Rothbard JB T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986, 324:258-260.
51. Tuohy VK, Sobel RA, Lees MB Susceptibility to PLP-induced EAE is regulated by non-H-2 genes. Ann N Y Acad Sci 1988, 540:709-711.
52. Mendel I, Kerlero de Rosbo N, Ben-Nun A A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 1995, 25:1951-1959.
53. Kojima K, Berger T, Lassmann H, et al. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia. J Exp Med 1994, 180:817-829.
54. Ben-Nun A, Wekerle H, Cohen IR The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur J Immunol 1981, 11:195-199.
55. Reboldi A, Coisne C, Baumjohann D, et al. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol 2009, 10:514-523.
56. Rothhammer V, Heink S, Petermann F, et al. Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE. J Exp Med 2011, 208:2465-2476.
57. Lees JR, Golumbek PT, Sim J, Dorsey D, Russell JH Regional CNS responses to IFN-gamma determine lesion localization patterns during EAE pathogenesis. J Exp Med 2008, 205:2633-2642.
58. Kroenke MA, Carlson TJ, Andjelkovic AV, Segal BM IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J Exp Med 2008, 205:1535-1541.
59. Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011, 479:538-541.
60. Sun D, Whitaker JN, Huang Z, et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 2001, 166:7579-7587.
61. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlén C, Goverman J A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001, 194:669-676.
62. Hjelmström P, Juedes AE, Fjell J, Ruddle NH B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J Immunol 1998, 161:4480-4483.
63. Oliver AR, Lyon GM, Ruddle NH Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J Immunol 2003, 171:462-468.
64. Molnarfi N, Schulze-Topphoff U, Weber MS, et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 2013, 210:2921-2937.
65. Linington C, Bradl M, Lassmann H, Brunner C, Vass K Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol 1988, 130:443-454.
66. Ajami B, Bennett JL, Krieger C, McNagny KM, Rossi FM Infiltrating monocytes trigger EAE progression, but do not contribute to the resident microglia pool. Nat Neurosci 2011, 14:1142-1149.
67. Heppner FL, Greter M, Marino D, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 2005, 11:146-152.
68. Goldmann T, Wieghofer P, Müller PF, et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci 2013, 16:1618-1626.
69. Locatelli G, Wörtge S, Buch T, et al. Primary oligodendrocyte death does not elicit anti-CNS immunity. Nat Neurosci 2012, 15:543-550.
70. Miller SD, Vanderlugt CL, Begolka WS, et al. Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. Nat Med 1997, 3:1133-1136.
71. Templeton SP, Perlman S Pathogenesis of acute and chronic central nervous system infection with variants of mouse hepatitis virus, strain JHM. Immunol Res 2007, 39:160-172.
72. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010, 362:387-401. the FREEDOMS Study Group.
73. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899-910. the AFFIRM Investigators.
74. Stüve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006, 59:743-747.
75. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012, 380:1829-1839. the CARE-MS II investigators.
76. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676-688. the HERMES Trial Group.
77. Panitch HS, Hirsch RL, Haley AS, Johnson KP Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1987, 1:893-895.
78. van Oosten BW, Rep MH, van Lier RA, et al. A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. J Neuroimmunol 1996, 66:49-55.
79. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999, 53:457-465. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
80. Havrdova E, Belova A, Goloborodko A, et al. Sensitivity analysis of a phase IIa study of secukinumab in relapsing remitting multiple sclerosis. Mult Scler 2013, 19:210-211.
81. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003, 102:2364-2372.
82. Lassmann H, Raine CS, Antel J, Prineas JW Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol 1998, 86:213-217.
83. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278-285.
84. Bitsch A, Schuchardt J, Bunkowski S, Kuhlmann T, Brück W Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000, 123:1174-1183.
85. Fischer MT, Sharma R, Lim JL, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012, 135:886-899.
86. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011, 134:1914-1924.
87. Witte ME, Nijland PG, Drexhage JA, et al. Reduced expression of PGC-1α partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex. Acta Neuropathol 2013, 125:231-243.
88. Nikić I, Merkler D, Sorbara C, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011, 17:495-499.
89. Davalos D, Ryu JK, Merlini M, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun 2012, 3:1227.
90. Shechter R, London A, Varol C, et al. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 2009, 6:e1000113.
91. Shechter R, Miller O, Yovel G, et al. Recruitment of beneficial M2 macrophages to injured spinal cord is orchestrated by remote brain choroid plexus. Immunity 2013, 38:555-569.
92. Miron VE, Boyd A, Zhao JW, et al. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci 2013, 16:1211-1218.
93. Kouwenhoven M, Teleshova N, Ozenci V, Press R, Link H Monocytes in multiple sclerosis: phenotype and cytokine profile. J Neuroimmunol 2001, 112:197-205.
94. Bar-Or A, Nuttall RK, Duddy M, et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain 2003, 126:2738-2749.
95. Yamasaki R, Lu H, Butovsky O, et al. Differential roles of microglia and monocytes in the inflamed central nervous system. J Exp Med 2014, 211:1533-1549.
96. Babbe H, Roers A, Waisman A, et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000, 192:393-404.
97. Jacobsen M, Cepok S, Quak E, et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 2002, 125:538-550.
98. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity. Nature 2012, 483:227-231.
99. Wakim LM, Woodward-Davis A, Bevan MJ Memory T cells persisting within the brain after local infection show functional adaptations to their tissue of residence. Proc Natl Acad Sci USA 2010, 107:17872-17879.
100. Siewert K, Malotka J, Kawakami N, Wekerle H, Hohlfeld R, Dornmair K Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides. Nat Med 2012, 18:824-828.
101. Kivisäkk P, Mahad DJ, Callahan MK, et al. Human cerebrospinal fluid central memory CD4+ T cells: evidence for trafficking through choroid plexus and meninges via P-selectin. Proc Natl Acad Sci USA 2003, 100:8389-8394.
102. Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
103. Sospedra M, Martin R Immunology of multiple sclerosis. Annu Rev Immunol 2005, 23:683-747.
104. Bielekova B, Goodwin B, Richert N, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000, 6:1167-1175.
105. Madsen LS, Andersson EC, Jansson L, et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 1999, 23:343-347.
106. Friese MA, Jakobsen KB, Friis L, et al. Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis. Nat Med 2008, 14:1227-1235.
107. Odoardi F, Sie C, Streyl K, et al. T cells become licensed in the lung to enter the central nervous system. Nature 2012, 488:675-679.
108. Kleinewietfeld M, Manzel A, Titze J, et al. Sodium chloride drives autoimmune disease by the induction of pathogenic TH17 cells. Nature 2013, 496:518-522.
109. Ascherio A, Munger KL, Lünemann JD The initiation and prevention of multiple sclerosis. Nat Rev Neurol 2012, 8:602-612.
110. Hedström AK, Bäärnhielm M, Olsson T, Alfredsson L Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis. Neurology 2009, 73:696-701.
111. Hedström AK, Olsson T, Alfredsson L High body mass index before age 20 is associated with increased risk for multiple sclerosis in both men and women. Mult Scler 2012, 18:1334-1336.
112. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007, 130:1089-1104.
113. Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005, 201:195-200.
114. Owens GP, Ritchie AM, Burgoon MP, Williamson RA, Corboy JR, Gilden DH Single-cell repertoire analysis demonstrates that clonal expansion is a prominent feature of the B cell response in multiple sclerosis cerebrospinal fluid. J Immunol 2003, 171:2725-2733.
115. von Büdingen HC, Kuo TC, Sirota M, et al. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest 2012, 122:4533-4543.
116. Palanichamy A, Apeltsin L, Kuo TC, et al. Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med 2014, 6:248ra106.
117. Obermeier B, Mentele R, Malotka J, et al. Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 2008, 14:688-693.
118. Bankoti J, Apeltsin L, Hauser SL, et al. In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol 2014, 75:266-276.
119. Dobson R, Ramagopalan S, Davis A, Giovannoni G Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013, 84:909-914.
120. Schirmer L, Srivastava R, Hemmer B To look for a needle in a haystack: the search for autoantibodies in multiple sclerosis. Mult Scler 2014, 20:271-279.
121. Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007, 204:2363-2372.
122. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012, 367:115-123.
123. Wucherpfennig KW, Strominger JL Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995, 80:695-705.
124. Hatterer E, Davoust N, Didier-Bazes M, et al. How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B-cell follicles of cervical lymph nodes. Blood 2006, 107:806-812.
125. Galea I, Bechmann I, Perry VH What is immune privilege (not)?. Trends Immunol 2007, 28:12-18.
126. Ransohoff RM, Engelhardt B The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012, 12:623-635.
127. Prodinger C, Bunse J, Krüger M, et al. CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system. Acta Neuropathol 2011, 121:445-458.
128. Mohammad MG, Tsai VW, Ruitenberg MJ, et al. Immune cell trafficking from the brain maintains CNS immune tolerance. J Clin Invest 2014, 124:1228-1241.
129. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science 2013, 342:373-377.
130. Eichler F, Van Haren K Immune response in leukodystrophies. Pediatr Neurol 2007, 37:235-244.
131. Trapp BD, Nave KA Multiple sclerosis: an immune or neurodegenerative disorder?. Annu Rev Neurosci 2008, 31:247-269.
132. Stys PK, Zamponi GW, van Minnen J, Geurts JJ Will the real multiple sclerosis please stand up?. Nat Rev Neurosci 2012, 13:507-514.
133. Confavreux C, Vukusic S, Moreau T, Adeleine P Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000, 343:1430-1438.
134. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010, 133:1900-1913.
135. Griffiths I, Klugmann M, Anderson T, et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 1998, 280:1610-1613.
136. Lappe-Siefke C, Goebbels S, Gravel M, et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat Genet 2003, 33:366-374.
137. Manrique-Hoyos N, Jürgens T, Grønborg M, et al. Late motor decline after accomplished remyelination: impact for progressive multiple sclerosis. Ann Neurol 2012, 71:227-244.
138. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003, 60:1157-1162.
139. Calabrese M, Rinaldi F, Mattisi I, et al. The predictive value of gray matter atrophy in clinically isolated syndromes. Neurology 2011, 77:257-263.
140. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
141. Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012, 135:2925-2937.
142. Merkler D, Ernsting T, Kerschensteiner M, Brück W, Stadelmann C A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain 2006, 129:1972-1983.
143. Gardner C, Magliozzi R, Durrenberger PF, Howell OW, Rundle J, Reynolds R Cortical grey matter demyelination can be induced by elevated pro-inflammatory cytokines in the subarachnoid space of MOG-immunized rats. Brain 2013, 136:3596-3608.
144. Hametner S, Wimmer I, Haider L, Pfeifenbring S, Brück W, Lassmann H Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol 2013, 74:848-861.
145. Werner P, Pitt D, Raine CS Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001, 50:169-180.
146. Pitt D, Nagelmeier IE, Wilson HC, Raine CS Glutamate uptake by oligodendrocytes: Implications for excitotoxicity in multiple sclerosis. Neurology 2003, 61:1113-1120.
147. Campbell GR, Ziabreva I, Reeve AK, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 2011, 69:481-492.
148. Yuseff MI, Pierobon P, Reversat A, Lennon-Duménil AM How B cells capture, process and present antigens: a crucial role for cell polarity. Nat Rev Immunol 2013, 13:475-486.